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Background:  The  long-term  survival  of  vasospastic  angina  (VSA)  patients  is generally  good,  so  long  as  they
remain  on  calcium  channel  blockers  (CCBs)  and  avoid  smoking.  However,  the  pathogenesis,  appropriate
treatments,  and  prognosis  of  VSA  associated  with  cardiac  arrest  remain  unclear.  This study  aimed  to
elucidate  the  clinical  features  and  long-term  outcomes  of  patients  with  VSA  associated  with  cardiac
arrest.
Methods  and  results:  Eighteen  consecutive  patients  with VSA  associated  with  cardiac  arrest  [13  patients
resuscitated  after  out-of-hospital  cardiac  arrest  (OHCA)  and  5 resuscitated  after  in-hospital-cardiac
arrest]  were  retrospectively  analyzed.  Sixteen  of the eighteen  patients  were smokers.  None  had  other
cardiac  diseases  possibly  causing  cardiac  arrest.  Although  1 patient  resuscitated  after  OHCA  later  died of
cerebral  hypoxia,  the  remaining  17 were  discharged  without  complications.  One  patient  died  of  cancer  50
months  after  resuscitation.  The  other  16 patients  are still  alive  and none  have  shown  ventricular  arrhyth-
mias,  syncope,  or  cardiac  arrest  during  a mean  follow-up  of  67  months.  All  are  treated  with  long-acting
CCBs/nitrates  and  successfully  quit smoking.  Six patients  received  implantable  cardioverter  deﬁbrilla-
tors  (ICD).  However,  none  demonstrated  any  ventricular  arrhythmias  and  appropriate  ICD actuation  was
achieved.
Conclusion:  Appropriate  medical  treatment  can  achieve  favorable  long-term  outcomes  even  for  patients
with  VSA  associated  with  cardiac  arrest.
3  Jap©  201
ntroduction
Vasospastic angina (VSA) is one of the causes of chest pain
ithout coronary artery stenotic lesions. The long-term survival
f VSA patients is generally good, so long as they remain on cal-
ium channel blockers (CCBs) and avoid smoking [1]. However,
ecent clinical studies have demonstrated that VSA might play an
mportant role in the pathogenesis of unexpected sudden cardiac
rrest (SCA) [2–11]. Takagi et al. reported that VSA patients who
urvived out-of-hospital cardiac arrest (OHCA) were a high-risk
opulation [2]. Therefore, decision-making on appropriate ther-
py including implantable cardioverter-deﬁbrillators (ICD) for VSA
atients resuscitated from SCA is an important topic in current
linical investigations. This study aimed to elucidate the clinical
∗ Corresponding author at: Division of Cardiology, Sendai City Hospital,
akabayashi-ku, Shimizukouji, 3-1, Sendai, Japan. Tel.: +81 022 266 7111;
ax: +81 022 211 8972.
E-mail  address: tetsuo.yagi@nifty.com (T. Yagi).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.06.011anese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
features and long-term outcomes of patients with VSA associated
with SCA in order to determine appropriate treatments for this
speciﬁc patient population.
Methods
This  was a retrospective, observational study in a single emer-
gency medical care center in Japan. The present study was  approved
by our institutional ethics committee. Informed consent from indi-
vidual patients was  not required under Japanese law as the present
study was  purely observational. Our hospital is a tertiary care refer-
ral center with intensive care units, coronary care units, and a
coronary intervention facility available 24 h a day, 7 days a week.
In total, 18 VSA patients resuscitated after SCA between 1992 and
2012 were identiﬁed in our hospital records. Thirteen patients were
resuscitated after OHCA. The other ﬁve patients were resuscitated
after in-hospital cardiac arrest; two patients (#14, 17) had been
admitted to our hospital to receive detailed evaluation of unex-
plained syncope, two (#15, 18) had been admitted to undergo
non-cardiac operations, and one (#16) had been admitted for
vier Ltd. All rights reserved.
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iabetes mellitus control. All patients had angiographically nor-
al coronary arteries. All patients fulﬁlled the following criteria
s described in previous studies [4–9]: (1) documented ventricu-
ar ﬁbrillation (VF) or sustained rapid ventricular tachycardia (VT)
r pulseless electrical activity; (2) the absence of signiﬁcant nar-
owing due to coronary atherosclerosis or any structural cardiac
bnormalities possibly causing cardiac arrest; (3) no previous his-
ory of angina pectoris or acute myocardial infarction; (4) absence
f identiﬁable or reversible causes of lethal ventricular arrhyth-
ias. A deﬁnite diagnosis of VSA was made in all patients according
o the Guidelines for Diagnosis and Treatment of Patients with
asospastic Angina of the Japanese Circulation Society [12]. VSA
as considered to be the cause of SCA if one of the following fea-
ures was noted: (1) spontaneous transient ST segment elevation
round the time of resuscitation; (2) spontaneous coronary artery
pasm during the emergent coronary angiogram obtained immedi-
tely after resuscitation; (3) a positive provocation test for coronary
rtery spasm and negative results of an electrophysiological study
EPS) to exclude idiopathic VF. The acetylcholine (ACh) provoca-
ion test was performed according to the method included in the
uidelines for Diagnosis and Treatment of Patients with Vasospas-
ic Angina of the Japanese Circulation Society [12]. The protocol for
PS has already been described [3,8,13,14]. Brieﬂy, the EPS protocol
ncluded burst pacing of up to 240 bpm and programmed stimula-
ion with up to 3 extra stimuli (minimum 200 ms)  with basic cycle
engths of 600 and 400 ms  from 2 sites in the right ventricle with
nd without isoproterenol infusion. EPS was identiﬁed as negative
hen sustained ventricular tachyarrhythmias were not induced.
linical characteristics, past medical history, situation at the time
f SCA, documented initial rhythm at the time of SCA, diagnostic
asis of SCA due to VSA, therapeutic contents post-resuscitation,
nd follow-up data were evaluated in each patient.
esults
Demographic and clinical data of the studied patients are out-
ined in Table 1. Fifteen patients (83%) were men  and 16 (88%) were
ctive smokers. Three patients (#9, 14, 17) were prescribed rel-
tively low doses of CCBs (diltiazem 60 mg/day in 1 patient and
mlodipine 5 mg/day in 2 patients) for treatment of hypertension
able 1
emographic and clinical data at resuscitation.
Patient number Age (yrs)
and  sex
Coronary risk
factors
Prescribed  CCBs
prior  to SCA
H
s
Survivors from out-of-hospital cardiac arrest
1 44 (M)  Smoking 0 0
2  58 (F) HT 0 0
3  55 (M)  Smoking 0 0
4  41 (M)  Smoking 0 0
5  68 (M)  Smoking/HT 0 0
6  70 (F) Smoking/HT/DL 0 0
7  44 (M)  Smoking 0 0
8  46 (F) 0 0 0
9  70 (M)  Smoking/HT Diltiazem/60 mga 0
10  49 (M)  Smoking/HT 0 0
11  58 (M)  Smoking/HT 0 0
12  48 (M)  Smoking/DL 0 0
13  59 (M)  Smoking 0 0
Survivors  from in-hospital cardiac arrest
14 65 (M)  Smoking/HT Amlodipine/5 mga +
15  65 (M)  Smoking 0 0
16  64 (M)  Smoking/DM 0 0
17  62 (M)  Smoking/HT Amlodipine/5 mga +
18  77 (M)  Smoking 0 0
CBs, calcium-channel blockers; DL, dyslipidemia; DM,  diabetes mellitus; F, female; HT, hy
ctivity;  SCA, sudden cardiac arrest; VF, ventricular ﬁbrillation.
a CCBs were prescribed for hypertension in those patients.rdiology 63 (2014) 41–45
prior  to SCA. Two patients (#14, 17) had a history of unexplained
syncope. Chest pain as a prodromal symptom of SCA was  docu-
mented in 7 patients (38%). Fourteen patients (77%) had suffered
SCA while at rest. Two patients (#15, 18) had suffered SCA dur-
ing a non-cardiac operation. VF as the initial rhythm at SCA was
documented in most patients (16 patients, 88%).
Diagnostic bases of VSA associated with SCA in the present study
population are listed in Table 2. Angiographically normal coro-
nary arteries were conﬁrmed by standard coronary angiography
in all patients. No one showed Brugada type electrocardiograms.
Spontaneous  ST elevation around the time of SCA was  documented
in 9 patients (50%). Furthermore, ST elevation transitioning to VF
was documented in 8 of these 9 patients. Spontaneous coronary
artery spasm was documented in 3 other patients (16%) during
emergent coronary angiography (CAG) immediately after resus-
citation. These 3 patients demonstrated severe coronary spasm
involving the entire right coronary artery. Intracoronary injection
of isosorbide dinitrate (ISDN) relieved the spasm in all 3 patients.
The remaining 6 patients (33%) were diagnosed based on positive
results of the ACh provocation test. Idiopathic VF was excluded by
EPS in 3 of these 6 patients. The other 3 patients refused EPS.
Treatments  and clinical courses in all patients are summarized
in Table 3. All patients were followed at our hospital. Although
patient #13 died of cerebral hypoxia 7 days after resuscitation, the
remaining 17 patients were discharged without complications. All
discharged patients achieved cessation of smoking. Daily multiple
doses of long-acting (24 h) CCBs were prescribed for most patients.
Only 1 patient (#12) was prescribed a daily single dose of amlodip-
ine because of intolerance to multiple doses of other CCBs. ISDN
was prescribed for 14 patients and nicorandil for 8. Although 2
patients (#5,9) complained of chest pain during follow-up because
of discontinuation of the medication, none showed evidence of
coronary spasm recurrence while continuously medicated. Patients
#5 and 9 resumed taking medications. Six patients underwent
ICD implantation at their request. However, none showed ven-
tricular arrhythmias. Therefore, the ICD was not activated. One
patient died of cancer 50 months after resuscitation. The other 16
patients are still alive and none has developed ventricular arrhyth-
mias, syncope, or cardiac arrest during a mean follow-up of 67
months.
istory  of
yncope
Prodromal
symptom
Situation at SCA Rhythm
at SCA
LVEF  (%)
 Chest pain At rest (morning) VF 60
 Syncope At rest (morning) VF 80
 Syncope At rest (day time) VF 65
 Syncope At rest (morning) VF 65
 Syncope At rest (evening) PEA 75
 Chest pain At rest (morning) PEA 87
 Chest pain At rest (morning) VF 66
 Chest pain At rest (morning) VF 60
 Chest pain At rest (morning) VF 52
 Syncope At rest (day time) VF 75
 Nausea At rest (day time) VF 60
 Syncope During exercise VF 67
 Syncope During effort VF 75
 Chest pain At rest (morning) VF 64
 0 During operation VF 64
 Chest pain At rest (morning) VF 65
 Syncope At rest (morning) VF 76
 0 During operation VF 70
pertension; LVEF, left ventricular ejection fraction; M,  male; PEA, pulseless electrical
Y. Yamashina et al. / Journal of Ca
Table  2
Diagnostic basis of sudden cardiac arrest due to vasospastic angina.a
Patient number
1 Documented transient ST elevation
2 Documented ST elevation transitioning to VF
3 Positive result of ACh provocation test
4 Documented ST elevation transitioning to VF
5 Spontaneous coronary artery spasm during CAG
immediately after resuscitation
6  Positive result of ACh provocation test/negative results
of  EPS
7 Positive result of ACh provocation test/negative results
of  EPS
8 Documented ST elevation transitioning to VF/positive
result of ACh provocation test
9 Spontaneous coronary artery spasm during CAG
immediately after resuscitation
10  Positive result of ACh provocation test
11 Positive result of ACh provocation test
12 Positive result of ACh provocation test/negative result
of  EPS
13 Spontaneous coronary artery spasm during CAG
immediately after resuscitation
14  Documented ST elevation transitioning to VF
15 Documented ST elevation transitioning to VF/positive
result of ACh provocation test
16  Documented ST elevation transitioning to VF
17 Documented ST elevation transitioning to VF
18 Documented ST elevation transitioning to VF
Ach, acetylcholine; CAG, coronary angiography; EPS, electrophysiological study; VF,
ventricular ﬁbrillation.
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da Angiographically normal coronary arteries were conﬁrmed by standard coro-
ary angiographies in all patients.
iscussion
Our ﬁndings suggest that appropriate medical treatment can
chieve favorable long-term outcomes even in patients with VSA
ssociated with SCA. In general, VSA patients have a good prognosis
o long as they remain on CCBs and avoid smoking [1]. However,
ecent clinical studies have demonstrated that VSA might play
n important role in the pathogenesis of SCA [2–11]. There is no
oubt that treatment with CCBs and nitrates is essential even in
SA patients resuscitated after SCA. However, the clinical impli-
ations of ICD for secondary prevention of malignant arrhythmias
ue to VSA are controversial. There are two conﬂicting theories
bout the outcomes of SCA survivors with VSA. Myerburg et al.
able 3
reatment and clinical course. .
Patient number Prescribed medications ICD
im
1 Diltiazem R/200 mg  bid, ISDN/40 mg  bid − 
2 Diltiazem R/200 mg  bid, nisoldipine/10 mg  bid, ISDN/40 mg bid − 
3 Nifedipine CR/40 mg bid, ISDN/40 mg  bid − 
4 Diltiazem R/200 mg  bid, ISDN/40 mg  bid, nicorandil/15 mg tid + 
5 Nifedipine CR/40 mg bid, ISDN/40 mg  bid, nicorandil/15 mg tid − 
6 Diltiazem R/200 mg  bid, nicorandil/15 mg  tid − 
7 Nifedipine CR/40 mg bid, nicorandil/15 mg  tid + 
8 Diltiazem R/200 mg  bid, benidipine/8 mg bid − 
9 Nifedipine CR/60 mg tid, ISDN/40 mg  bid + 
10 Nifedipine CR/40 mg bid, ISDN/40 mg  bid + 
11 Nifedipine CR/40 mg bid, ISDN/40 mg  tid + 
12 Amlodipine/5 mg  q.d., ISDN/40 mg  bid + 
13
14 Nifedipine CR/60 mg tid, ISDN/40 mg  bid, nicorandil/20 mg qid − 
15 Diltiazem R/200 mg  bid, ISDN/80 mg  qid, − 
16 Diltiazem R/200 mg  bid, ISDN/40 mg  bid, nicorandil/15 mg tid − 
17 Nifedipine CR/60 mg tid, ISDN/60 mg  tid, nicorandil/15 mg tid − 
18 Nifedipine CR/40 mg bid, ISDN/40 mg  bid − 
CD, implantable cardioverter-deﬁbrillator; ISDN, isosorbide dinitrate; PEA, pulseless ele
ied  of cerebral hypoxia 7 days after resuscitation.rdiology 63 (2014) 41–45 43
[4],  Chevalier et al. [5], and Meune et al. [7] reported that neither
lethal ventricular arrhythmias nor SCA recurred when survivors of
SCA caused by coronary spasm were maintained on appropriate
CCB therapy. On the other hand, Meisel et al. reported recurrence
of lethal ventricular arrhythmias in 100% (8/8) of survivors of SCA
caused by coronary spasm [6]. The difference in patients between
the former 3 studies and the latter study was  the state of recur-
rent angina control by CCB treatment after discharge. Although
patients in the former 3 studies had been symptom-free during
follow up with appropriate CCB treatment, most patients (7 of 8)
in the latter study had recurrent episodes of angina after discharge.
Insufﬁcient CCB dosage for the prevention of transient narrowing
of coronary arteries might have led to recurrent angina and eventu-
ally lethal ventricular arrhythmias in patients in the latter study. In
fact, 3 patients (#9, 14, 17) in the present study had been prescribed
relatively low-dose CCBs as treatment for hypertension prior to
SCA. These 3 patients are now symptom-free on stronger CCBs.
In addition, discontinuation of the CCBs/nitrate resulted in recur-
rent angina episodes in 2 patients (#5, 9) after discharge. These
results highlight the importance for SCA–VSA patients of deter-
mining the optimal dosages of CCBs/nitrate before discharge and
of continuing medical treatment. Myerburg et al. [4] and Chevalier
et al. [5] reported the usefulness of repeated ergonovine provo-
cation tests to determine the most appropriate CCB dosages for
SCA–VSA patients.
Another important issue in the management of SCA survivors
with VSA is the methodology used to appropriately diagnose SCA
caused by VSA. Recently, Matsue et al. reported ICD to be useful
for SCA survivors with VSA because of their high risk for recur-
rence of cardiopulmonary arrest [9]. However, all patients in their
study were diagnosed as having VSA employing ACh provocation
tests several days after resuscitation. Therefore, the diagnostic evi-
dence of SCA due to VSA was indirect in Matsue et al.’s cohort [9].
It cannot be denied that VSA diagnosed by the ACh/ergonovine
provocation test several days after resuscitation is an innocent
bystander to SCA. Although Takagi et al. also reported that of
10 consecutive SCA survivors with VSA diagnosed by ACh provo-
cation test, who  underwent ICD insertion, only 1 patient with
Brugada syndrome was conﬁrmed to have experienced an appro-
priate ICD shock during follow up [3]. VSA and Brugada syndrome
are well known to often coexist [15,16]. We  advocate that VSA
patients with other VF risk factors, such as Brugada syndrome
or idiopathic VF need to be differentiated from “pure” SCA–VSA
plantation
Recurrence of
chest  pain
Recurrence of
SCA  (VF/PEA)
ICD shocks Follow up
(months)
0 0 252
0 0 240
0 0 84
0 0 0 60
+ 0 60
0 0 52
0 0 0 46
0 0 21
+ 0 0 20
0 0 0 10
0 0 0 10
0 0 0 6
0 0 69
0 0 62
0 0 60
0 0 58
0 0 39
ctrical activity; SCA, sudden cardiac arrest; VF, ventricular ﬁbrillation. Patient #13
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nary  spasm by intracoronary injection of acetylcholine and/or ergonovine4 Y. Yamashina et al. / Journa
atients. In the present study, we obtained direct evidence of coro-
ary artery spasm (i.e. transient ST elevation immediately after
esuscitation, ST elevation transitioning to VF, and spontaneous
oronary spasm during CAG immediately after resuscitation) in
2 of 18 (66%) patients. Furthermore, in all remaining patients,
xcept those who refused EPS, idiopathic VF was excluded as a
ause of SCA by EPS. We  believe our study population to be com-
osed of “pure” SCA–VSA patients and that the prognosis of such
atients is favorable with maintenance therapy including mul-
iple doses of long-acting CCBs/nitrates and successful smoking
essation. However, ICD might be useful for patients who have
ther risk factors such as poor compliance with medical treat-
ent (CCBs/nitrates) or management of daily life (correction of
isk factors), coexisting Brugada syndrome or other idiopathic VF,
nd concomitance of decreased cardiac function. In fact, Cheva-
ier et al. [5] reported that only one patient who did not stop
moking experienced recurrence of SCA and needed ICD implan-
ation in their case series of SCA–VSA patients. Takagi et al. [2]
lso reported a recurrence of SCA in the patient who  terminated
edication by himself. A careful assessment of each patient’s back-
round, close follow-up, and continuous education are necessary
17].
The present study has several limitations. First, although the
resent study population was relatively large as compared to those
f previous studies that reported clinical characteristics and out-
omes of SCA survivors complicated by VSA [2–9], the present
tudy was a small, retrospective, and non-randomized study in
 single Japanese center. Further prospective multicenter stud-
es including more patients from multiple ethnic populations
re required to conﬁrm the outcomes of SCA–VSA patients. Fur-
hermore, the present study did not randomize patients to the
CD implanted group or the non-ICD implanted group. There-
ore, the potential usefulness of ICD in preventing the recurrence
f SCA was not validated in the present study design. However,
ll discharged patients in the present study did not show evi-
ence of recurrence of VF and/or SCA during follow-up. If we
ad conducted randomization for the present study population,
e would not have been able to show the prognostic superi-
rity of ICD-implanted patients. In addition, randomization of
reatment for SCA survivors is often difﬁcult and illicit in clinical
ettings. Second, we did not perform intracoronary observations
y using an intravascular imaging modality such as intravascular
ltrasound (IVUS) or intravascular optical coherence tomogra-
hy (OCT) for the present study population. Previous studies
sing IVUS or OCT have demonstrated that the nature of intra-
oronary plaques and endothelial abnormalities play important
oles in the disease progression and pathogenesis of VSA, even in
atients with normal coronary angiograms [18–20]. Considering
he fewer acute coronary events in patients with VSA, coronary
laque vulnerability may  be more stable than in organic coro-
ary atherosclerosis. However, considering that the response to
reatment with CCBs/nitrates often differs among patients with
SA, the coronary plaque burden or the nature of endothelial dys-
unction may  be different between a recalcitrant VSA case and an
asily controlled one. Further clinical studies on SCA–VSA cases by
sing IVUS or OCT will be useful to clarify the risk stratiﬁcation
n SCA–VSA patients. Third, although the possibility of idiopathic
F as a cause of SCA in the 3 patients (#3, 10, 11) who  refused
PS cannot be excluded, 2 of these 3 patients underwent ICD
nsertion for backup. One patient (#3) refused ICD. It is often difﬁ-
ult to document direct evidence of coronary spasm causing SCA.
herefore, further studies are needed to elucidate the appropriate
ethod to diagnose “pure” VSA–SCA patients. Fourth, we  did not
epeat ACh/ergonovine provocation tests to determine the optimal
osages of CCBs/nitrate. Further studies are needed to clarify the
[rdiology 63 (2014) 41–45
methods  for determining appropriate dosages of medications used
to treat SCA–VSA patients.
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